

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33

Universal screening for SARS-CoV-2 infection among pregnant women at Elmhurst Hospital Center, Queens, New York

Sheela Maru<sup>1,2,3\*</sup>, Uday Patil<sup>3,4</sup>, Rachel Carroll-Bennett<sup>2,3</sup>, Aaron Baum<sup>1</sup>, Tracy Bohn-Hemmerdinger<sup>2,3</sup>, Andrew Ditchik<sup>2,3</sup>, Michael L Scanlon<sup>1</sup>, Parvathy Krishnan<sup>3,4</sup>, Kelly Bogaert<sup>2,3</sup>, Carson Woodbury<sup>2,3</sup>, Duncan Maru<sup>1,3</sup>, Lawrence Noble<sup>3,4</sup>, Randi Wasserman<sup>3,4</sup>, Barry Brown<sup>2,3</sup>, Rachel Vreeman<sup>1,3</sup>, Joseph Masci<sup>3,5</sup>

<sup>1</sup> Department of Health System Design and Global Health and the Arnhold Institute for Global Health, Icahn School of Medicine at Mount Sinai, New York City, NY, USA

<sup>2</sup> Department of Obstetrics, Gynecology and Reproductive Science at the Icahn School of Medicine at Mount Sinai, New York City, NY, USA

<sup>3</sup> New York City Health + Hospitals/Elmhurst, New York City, NY, USA

<sup>4</sup> Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York City, NY, USA

<sup>5</sup> Department of Medicine, Icahn School of Medicine at Mount Sinai, New York City, NY, USA

\* Corresponding author:

Email: [Sheela.Maru@mssm.edu](mailto:Sheela.Maru@mssm.edu) (SM)

## 34 **Abstract**

35

## 36 **Background**

37 Universal screening for SARS-CoV-2 infection on Labor and Delivery (L&D)  
38 units is a critical strategy to manage patient and health worker safety, especially in a  
39 vulnerable high-prevalence community. We describe the results of a SARS-CoV-2  
40 universal screening program at the L&D Unit at Elmhurst Hospital in Queens, NY, a 545-  
41 bed public hospital serving a diverse, largely immigrant and low-income patient  
42 population and an epicenter of the global pandemic.  
43

## 44 **Methods and findings**

45 We conducted a retrospective cross-sectional study. All pregnant women admitted  
46 to the L&D Unit of Elmhurst Hospital from March 29, 2020 to April 22, 2020 were  
47 included for analysis. The primary outcomes of the study were: (1) SARS-CoV-2  
48 positivity among universally screened pregnant women, stratified by demographic  
49 characteristics, maternal comorbidities, and delivery outcomes; and (2) Symptomatic or  
50 asymptomatic presentation at the time of testing among SARS-CoV-2 positive women.

51 A total of 126 obstetric patients were screened for SARS-CoV-2 between March  
52 29 and April 22. Of these, 37% were positive. Of the women who tested positive, 72%  
53 were asymptomatic at the time of testing. Patients who tested positive for SARS-CoV-2  
54 were more likely to be of Hispanic ethnicity (unadjusted difference 24.4 percentage  
55 points, CI 7.9, 41.0) and report their primary language as Spanish (unadjusted difference  
56 32.9 percentage points, CI 15.8, 49.9) than patients who tested negative.  
57

## 58 **Conclusions**

59 In this retrospective cross-sectional study of data from a universal SARS-Cov-2  
60 screening program implemented in the L&D unit of a safety-net hospital in Queens, New  
61 York, we found over one-third of pregnant women testing positive, the majority of those  
62 asymptomatic. The rationale for universal screening at the L&D Unit at Elmhurst  
63 Hospital was to ensure safety of patients and staff during an acute surge in SARS-Cov-2  
64 infections through appropriate identification and isolation of pregnant women with  
65 positive test results. Women were roomed by their SARS-CoV-2 status given increasing  
66 space limitations. In addition, postpartum counseling was tailored to infection status. We  
67 quickly established discharge counseling and follow-up protocols tailored to their specific  
68 social needs. The experience at Elmhurst Hospital is instructive for other L&D units  
69 serving vulnerable populations and for pandemic preparedness.  
70  
71  
72  
73  
74  
75  
76  
77  
78

79

80

81

82

## 83 **Introduction**

84           New York City (NYC) has been a global epicenter of the SARS-CoV-2 outbreak,  
85 accounting for 17% of confirmed cases in the United States, as of April 25, 2020 [1]. In  
86 the initial response, SARS-CoV-2 testing in NYC focused on symptomatic individuals at  
87 testing centers or emergency departments and hospitalized patients [2]. Asymptomatic  
88 infected individuals may contribute substantially to transmission, including in hospital  
89 settings [3-9]. The fraction of SARS-CoV-2 infections in NYC that are asymptomatic – a  
90 key parameter for epidemiological models that forecast rates of infection, hospitalization,  
91 and death – is unknown. Moreover, much of the available data is not stratified by socio-  
92 demographic characteristics, which is critical to understand health disparities [10].

93           Labor and delivery (L&D) wards were some of the first places where universal  
94 screening for SARS-CoV-2 was instituted in the US. On March 29, 2020, the L&D Unit  
95 at Elmhurst Hospital in Queens, NYC instituted universal screening in order to manage  
96 care and isolation of admitted patients. The primary objective of this study was to  
97 describe the prevalence of SARS-CoV-2 infection, stratified by socio-demographic data,  
98 and symptom presentation among universally screened pregnant women. We explain the  
99 rationale, implications, and significance of screening in this public hospital caring for a  
100 severely affected and vulnerable population.

101

## 102 **Methods**

## 103 **Study design and setting**

104 We retrospectively reviewed medical charts of all pregnant women who were  
105 universally screened for SARS-CoV-2 on admission to the L&D Unit at Elmhurst  
106 Hospital. Elmhurst Hospital is a 545-bed public hospital that serves a diverse, largely  
107 immigrant and low-income patient population. The hospital serves about 134,000 patients  
108 per year and performs 2,200 deliveries annually [11]. The hospital has been hard hit by  
109 the pandemic, caring for 2,920 known COVID-19 cases as of May 4, 2020 [12].

## 110 **Participants and data collection**

111 We included all pregnant women admitted to the L&D Unit at Elmhurst Hospital  
112 from March 29, 2020 to April 22, 2020. This time period was selected as it comprised the  
113 ‘surge’ of cases in NYC. Study size was limited by the time period. Demographic and  
114 clinical data were extracted from the electronic medical record (EPIC) both using a data  
115 extraction tool (SlicerDicer) and manually, then de-identified manually and assigned a  
116 random study number. SARS-CoV-2 testing was performed using nasopharyngeal swabs  
117 and the results were from BioReference Laboratories and the Elmhurst Hospital  
118 Laboratory (Cepheid Rapid PCR). Primary outcomes were SARS-CoV-2 test result  
119 (positive/negative/invalid) and the presence of SARS-CoV-2 symptoms on admission.  
120 Demographic data included age, ethnicity, primary language, marital status (‘not married’  
121 includes single and divorced statuses), health insurance status (public, private and  
122 uninsured), and zip code. Race was not included due to the poor quality of the data in the  
123 medical record. Clinical data included SARS-CoV-2 test result, SARS-CoV-2 symptoms,  
124 gestational age at delivery (divided into term and preterm), mode of delivery (vaginal  
125 delivery includes assisted vaginal deliveries), comorbidities, and length of stay. The

126 comorbidities we assessed were as follows: hypertensive disorders (chronic hypertension,  
127 gestational hypertension, preeclampsia, superimposed preeclampsia), pre-pregnancy  
128 maternal obesity, asthma or pulmonary disease, diabetes (pre-gestational and gestational),  
129 infectious disease (HIV, hepatitis B), depression or anxiety, and other significant  
130 maternal disease including heart, kidney, or thyroid disease.

## 131 **Statistical analysis**

132 We describe SARS-CoV-2 test positivity and the symptom status at admission  
133 among positive patients. Test positivity is stratified by sociodemographic characteristics,  
134 maternal comorbidities, and delivery outcomes. Demographic characteristics, maternal  
135 comorbidities, and delivery outcomes of patients who tested positive versus negative for  
136 SARS-CoV-2 were compared using 2-sided unpaired t-tests, with unadjusted differences  
137 and 95% confidence intervals (CI) reported.

## 138 **Ethical approval**

139 This study was approved by the Institutional Review Board at the Icahn School of  
140 Medicine at Mount Sinai, IRB-20-03424, and approved by NYC Health + Hospitals.

141

## 142 **Results**

143 One hundred percent of admissions to the L&D Unit during the study period were  
144 tested. Two women had invalid test results and were excluded from analysis. Among the  
145 remaining 124 women, the mean age was 30.2 years, 78 (62.9%) were Hispanic, 26  
146 (20.1%) were Asian, and 112 (90.3%) had public insurance. 78.3% of patients who tested  
147 positive for SARS-CoV-2 identified their ethnicity as Hispanic compared to 53.9% of

148 patients who tested negative, a significant difference of 24.4 percentage points (95% CI:  
 149 7.9, 41.0). Similarly, 73.9% of patients who tested positive for SARS-CoV-2 self-  
 150 reported their primary language as Spanish compared to 41.0% of patients who tested  
 151 negative, a significant difference of 32.9 percentage points (95% CI: 15.8, 49.9). There  
 152 was not a statistically significant difference in other demographic characteristics or rates  
 153 of maternal comorbidities between patients who tested positive versus negative for  
 154 SARS-CoV-2 (Table 1).

155

156 **Table 1. SARS-CoV-2 Test Results among 124 Obstetrical Patients Admitted to**  
 157 **Labor and Delivery, by Demographic Characteristics**

Variable	SARS-CoV-2 Positive No. (%)	SARS-CoV-2 Negative No. (%)	Unadjusted Difference (CI)
<b>Total Number</b>	46	78	--
<b>Age (years)</b>			
< median (30 years)	20 (43.5%)	43 (55.1%)	-11.6 (-30.1, 6.7)
> median (30 years)	26 (56.5%)	35 (44.9%)	
<b>Ethnicity</b>			
<b>Hispanic</b>	36 (78.3%)	42 (53.9%)	24.4 (7.9, 41.0)
<b>Not Hispanic</b>	10 (21.7%)	36 (46.2%)	
<b>Primary Language</b>			
<b>Spanish</b>	34 (73.9%)	32 (41.0%)	32.9 (15.8, 49.9)
<b>Other</b>	12 (26.1%)	46 (59.0%)	
<b>Marital status</b>			
<b>Married</b>	19 (41.3%)	36 (46.2%)	-4.8 (-23.2, 13.5)
<b>Not Married</b>	27 (58.7%)	42 (53.9%)	
<b>Insurance status</b>			
<b>Public</b>	43 (93.5%)	69 (88.5%)	5.0 (-5.2, 15.3)

<b>Other</b>	3 (6.5%)	9 (11.5%)	
<b>Comorbidities</b>			
<b>≥ 1</b>	26 (56.5%)	35 (44.9%)	11.6 (-6.8, 30.1)
<b>None</b>	20 (43.5%)	43 (55.1%)	
<b>Current or Prior Smoker</b>			
<b>Yes</b>	2 (4.4%)	5 (6.4%)	-2.1 (-10.2, 6.1)
<b>No</b>	44 (95.7%)	73 (93.6%)	

158  
159

160           Forty-six of 124 (37.1%) screened pregnant women had a positive SARS-CoV-2  
161 test. Of those, 33 (71.7%) were asymptomatic and 13 (28.3%) were symptomatic (Fig 1).  
162 Of those women who were symptomatic, the median number of symptoms on admission  
163 was 2, with the most common symptoms fever and cough. Other symptoms that were  
164 reported by patients in this cohort included body aches, sore throat, shortness of breath or  
165 difficulty breathing, headache, and runny nose. The presence of symptoms did not appear  
166 to be related to the mode of delivery or associated with preterm delivery. Of note, during  
167 our study period there were no maternal deaths.

168 **Fig 1. SARS-CoV-2 Symptoms on Admission and Test Results among 126**  
169 **Obstetrical Patients Presenting for Delivery**  
170

171

172           Among 38 SARS-CoV-2 positive women who delivered by the time of data  
 173 collection, 35 (92.1%) had a term delivery and 25 (65.8%) had a vaginal delivery. This  
 174 was similar to 74 SARS-CoV-2 negative women who delivered by the time of data  
 175 collection, among whom 78 (87.8%) had a term delivery and 49 (66.2%) had a vaginal  
 176 delivery. A significantly greater percentage of women who tested positive for SARS-  
 177 CoV-2 had a length of stay greater than or equal to 48 hours compared to women who  
 178 tested negative (45.7% vs 25.6%, unadjusted difference of 20.0 percentage points, 95%  
 179 CI: 2.3, 37.7). (Table 2).

180 **Table 2. SARS-CoV-2 Test Results among 124 Obstetrical Patients Admitted to**  
 181 **Labor and Delivery, by Delivery Outcome**

182

<b>Variable</b>	<b>SARS-CoV-2 Positive No. (%)</b>	<b>SARS-CoV-2 Negative No. (%)</b>	<b>Unadjusted Difference (CI)</b>
<b>Total Number</b>	46	78	--
<b>Gestational Age <sup>a,b</sup></b>			
<b>Term</b>	35 (92.1%)	65 (87.8%)	4.3 (-7.3, 15.9)
<b>Preterm</b>	3 (7.9%)	9 (12.2%)	
<b>Mode of Delivery <sup>b</sup></b>			
<b>Vaginal</b>	25 (65.8%)	49 (66.2%)	0.4 (-18.5, 19.3)
<b>Cesarean</b>	13 (34.2%)	25 (33.8%)	
<b>Length of Stay</b>			
<b>≥48 hours</b>	21 (45.7%)	20 (25.6%)	20.0 (2.3, 37.7)
<b>&lt;48 hours</b>	25 (54.4%)	58 (74.4%)	

183

184 <sup>a</sup> At time of delivery.

185 <sup>b</sup> Excludes 12 patients who were still pregnant at the time of data collection.

186

187           Seventy-eight of the screened women resided in one of 4 zip-codes, with the  
188 remaining residing across 29 distinct zip-codes. The NYC Department of Health and  
189 Mental Hygiene reported that, as of April 22, 2020, these 4 zip-codes had a SARS-CoV-2  
190 test-positive rate of 59% to 79% for the general population [9]. In our data, women  
191 residing in these top four zip-codes had a test-positive rate of 30.4%.

192

## 193 **Discussion**

194 Our study represents one of the few published studies of universal screening for SARS-  
195 CoV-2. We found that over one third of pregnant women tested positive for SARS-CoV-  
196 2 at the L&D Unit at Elmhurst. Selection bias may have been present as pregnant women  
197 with SARS-CoV-2 infection or symptoms may have been more likely to present for  
198 admission. However, this is significantly higher than results published from universal  
199 screening conducted at L&D Units in other NYC hospitals [8, 13-14]. A study among  
200 215 pregnant women at New York-Presbyterian Allen Hospital and Columbia University  
201 Irving Medical Center found that 15% tested positive for SARS-CoV-2, and another  
202 among 161 pregnant women at NYU Winthrop Hospital found that 20% tested positive  
203 for SARS-CoV-2.

204           The higher rate of infection at Elmhurst Hospital is likely secondary to the  
205 demographics of the surrounding population. Over 200,000 Queens residents live in  
206 crowded homes, and 70,000 in severely crowded homes [15]. Recent data from NYC  
207 show a lower rate of infection for non-hospitalized Hispanic patients compared with  
208 Black or White patients; however, these data on race and ethnicity that come from  
209 laboratory reports were noted to be only 40% complete. Our universal screening data

210 show significantly higher rates of infection among Hispanics compared to non-Hispanics,  
211 which is more consistent with data among all hospitalized patients in NYC [16]. Gaps in  
212 data are likely obscuring disparities.

213         The cross-sectional association we observed between test-positivity and Hispanic  
214 ethnicity and Spanish as a primary language may be confounded by patients'  
215 socioeconomic status. At Elmhurst Hospital we serve a largely immigrant (foreign-born),  
216 resource-poor population. The primary language of Spanish likely indicates the patient  
217 was not born in the USA or is a first-degree descendant of Latin American immigrants  
218 (although there may be exceptions). Both of these characteristics are common in our  
219 patient population. Additionally, Spanish as a preferred language may indicate barriers to  
220 seeking or utilizing healthcare, which may affect co-morbidities and infection rates.

221         When looking at mode of delivery and gestational age at delivery, no significant  
222 difference in either of these was noted between the SARS-CoV-2 positive and negative  
223 mothers. SARS-CoV-2 status was not an indication for cesarean section or for preterm  
224 induction of labor.

225         The increased length of stay in the symptomatic patients is likely secondary to the  
226 severity of illness being greater in symptomatic patients. In order to warrant admission  
227 for SARS-Cov-2 symptoms typically maternal fever had to be accompanied by either  
228 maternal or fetal tachycardia, shortness of breath or decreased oxygen saturation on room  
229 air, or concerning findings on chest X-ray for possible pneumonia. Patients who did not  
230 meet these criteria, and had normal vital signs apart from fever, and reassuring fetal  
231 testing were typically assessed in our triage area and discharged home rather than  
232 admitted. These patients who were not admitted would not have been included in this

233 cohort. The criteria for discharge among symptomatic patients included normalization of  
234 vital signs, specifically remaining afebrile and having oxygen saturation of over 95%  
235 consistently on room air both at rest and with ambulation.

236 Our first Obstetric SARS-CoV-2 case was March 15. Early in the pandemic, when  
237 we tested based on symptoms and history alone, several obstetric patients were admitted  
238 for birth asymptomatic and were later readmitted with severe COVID-19 infection. We  
239 were concerned about the likely spread to staff and other patients within our unit from  
240 pre-symptomatic and asymptomatic women. At the same time, our hospital was quickly  
241 becoming the epicenter of cases in the US, and all available physical space was required  
242 to care for COVID-19 patients. A large part of the postpartum unit was needed for non-  
243 obstetric COVID-19 care, and we suddenly had limited capacity to isolate positive  
244 postpartum women and those with unknown status. Upon this structural change, we  
245 began universal screening of pregnant women with planned or unplanned admission. One  
246 limitation of our study was the use of two different test types for universal screening. We  
247 were initially using BioReference Laboratory tests which returned in several days, and as  
248 rapid tests became available we switched to the Cepheid Rapid PCR. These tests likely  
249 had different sensitivities and specificities (though we were not provided with this  
250 information) and may have affected our screening results.

251 SARS-CoV-2 screening fundamentally shifted the way we roomed, counseled,  
252 and followed women (Fig 2). Cohorting women by SARS-CoV-2 infection status allowed  
253 us to most safely use the restricted space. Several walls were built to further partition the  
254 space in the triage, labor, and postpartum areas in order to ensure separation of SARS-  
255 CoV-2 positive women and those of unknown status from women known to be negative.

256 In the early days of the pandemic, SARS-CoV-2 positive mothers were roomed  
257 separately from their infants, however, this procedure was reconsidered as the volume of  
258 known SARS-CoV-2 positive mothers increased with universal screening. Given limited  
259 physical space and staff to isolate all infants and considering the importance of  
260 simulating the home-environment during the postpartum hospitalization to promote safe  
261 infant care and breastfeeding, we proceeded with shared decision making with SARS-  
262 CoV-2 positive mothers around rooming-in with their infants. Severe overcrowding of  
263 housing is a challenge where most of our mothers live, making isolation of a baby and  
264 mother in the home-setting infeasible for most. We educated women on appropriate PPE  
265 use, breastfeeding, and social distancing measures that families could utilize upon  
266 discharge home. We postponed postpartum maternal vaccinations for SARS-CoV-2  
267 positive women to eliminate any confusion between vaccine-related fever and COVID-19  
268 symptoms (those who were SARS-CoV-2 negative received routine postpartum  
269 vaccination). Additionally, upon discharge we provided infected and PUI (Person Under  
270 Investigation) mothers with surgical facemasks and single-use Tempa-DOT  
271 thermometers, as the pharmacies in the surrounding zip-codes had none available. Our  
272 clinicians actively followed our infected and PUI mothers via phone after discharge,  
273 screening for symptoms and access to thermometers and acetaminophen.

274

275 **Fig 2. Strategies Employed by the Labor and Delivery Unit at Elmhurst Hospital**  
276 **during the Initial Phase of the SARS-CoV-2 Outbreak**

277

278 We found high rates of asymptomatic SARS-CoV-2 infection among pregnant  
279 women; these screening data and our experience at a large public hospital at the epicenter

280 of the nation's pandemic are instructive. In future epidemics, it may be prudent to look at  
281 L&D screening numbers early on, as pregnant women continue to seek essential care  
282 despite social distancing measures and also represent the general young and healthy  
283 community population. Additionally, this experience illustrates a nimble response to an  
284 acute shortage of space and PPE for hard-hit vulnerable communities.

285

## 286 **Acknowledgements**

287 We would like to acknowledge the staff of Obstetrics and Gynecology and Pediatrics at  
288 Elmhurst Hospital who cared for our community under stress, the women who showed  
289 such bravery during pregnancy and delivery in the face of the pandemic, and the  
290 COVID-19 Unit for Research at Elmhurst for the timely research support.

291

## 292 **Author Contributions**

293 Conceptualized the screening protocol, inpatient care and postpartum follow-up: BB, AD,  
294 TB, UP, RW. Conceptualized the study: SM, JM. Collected the data: RC, SM, PK.  
295 Methodology development, data analysis, interpretation: AB, SM, DM, RC, UP, PK, LN,  
296 RW, MS, BB. Contributed to the writing and editing of the manuscript: SM, UP, RC, AB,  
297 TB, AD, MS, LN, RW, KB, CW, DM, BB, RV. All authors meet ICMJE criteria for  
298 authorship and all authors read and approved the final manuscript.

299

300

## 301 **References**

302

303 1. Wadhera RK, Wadhera P, Gaba P, et al. Variation in COVID-19 Hospitalizations  
304 and Deaths Across New York City Boroughs. *JAMA*. 2020;323(21):2192–2195.

305 2. Shear M, Goodnough A, Kaplan S, Fink S, Thomas K, Weiland N. The lost  
306 month: How a failure to test blinded the U.S. to Covid-19. *The New York Times*. 2020  
307 Mar 28 [Cited 2020 Apr 1]. Available from:

308 <https://www.nytimes.com/2020/03/28/us/testing-coronavirus-pandemic.html>

309 3. Wei WE, Li Z, Chiew CJ, Yong SE, Toh MP, Lee VJ. Presymptomatic  
310 Transmission of SARS-CoV-2 - Singapore, January 23-March 16, 2020. *MMWR Morb*  
311 *Mortal Wkly Rep*. 2020;69(14):411-5.

312 4. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic  
313 proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond  
314 Princess cruise ship, Yokohama, Japan, 2020. *Euro Surveill*. 2020;25(10).

315 5. Krieger N, Gonsalves G, Bassett MT, Hanage W, Krumholz HM. *Health Affairs*  
316 *Blog*. 2020 Apr 14 [Cited 2020 Apr 20]. Available from:

317 <https://www.healthaffairs.org/doi/10.1377/hblog20200414.238084/full/>

318 6. Khoury R, Bernstein PS, Debolt C, et al. [Characteristics and Outcomes of 241](#)  
319 [Births to Women With Severe Acute Respiratory Syndrome Coronavirus 2 \(SARS-CoV-](#)  
320 [2\) Infection at Five New York City Medical Centers](#). *Obstetrics & Gynecology*. 2020;  
321 [136\(2\): 273-282](#).

322 7. Miller ES, Grobman WA, Sakowicz A, et al. [Clinical Implications of Universal](#)  
323 [Severe Acute Respiratory Syndrome Coronavirus 2 \(SARS-CoV-2\) Testing in](#)  
324 [Pregnancy](#). *Obstetrics & Gynecology*. 2020; 136(2): 232-234.

325 8. Bianco A, Buckley AB, Overbey J, et al. [Testing of Patients and Support Persons](#)  
326 [for Coronavirus Disease 2019 \(COVID-19\) Infection Before Scheduled Deliveries](#).  
327 *Obstetrics & Gynecology*. 2020; 136(2): 283-287.

328 9. Andrikopoulou M, Madden N, Wen T, et al. [Symptoms and Critical Illness](#)  
329 [Among Obstetric Patients With Coronavirus Disease 2019 \(COVID-19\) Infection](#).  
330 *Obstetrics & Gynecology*. 2020; 136(2): 291-299.

331 10. Community health needs assessment 2019. New York: NYC Health + Hospitals,  
332 OneCity Health; 2019 Jun 30 [Cited 2020 Apr 1]. Available from:

333 <https://hhinternet.blob.core.windows.net/uploads/2019/08/chna-2019.pdf>

334 11. Rothfeld M, Sengupta S, Goldstein J, Rosenthal B. 13 deaths in a day: an  
335 ‘apocalyptic’ coronavirus surge at an NYC hospital. *The New York Times*. 2020 Mar 25  
336 [Cited 2020 Apr 1]. Available from: [https://www.nytimes.com/2020/03/25/nyregion/nyc-](https://www.nytimes.com/2020/03/25/nyregion/nyc-coronavirus-hospitals.html)  
337 [coronavirus-hospitals.html](#)

338 12. COVID-19: Data. NYC Health. [Cited 2020 Apr 15]. Available from:

339 <https://www1.nyc.gov/site/doh/covid/covid-19-data.page>

340 13. Sutton D, Fuchs K, D’Alton M, Goffman D. Universal Screening for SARS-CoV-  
341 2 in Women Admitted for Delivery. *New England Journal of Medicine*. 2020 Apr 13  
342 [Cited 2020 Apr 20]. Available from:


343 <https://www.nejm.org/doi/full/10.1056/NEJMc2009316>

344 14. Vintzileos WS, Muscat J, Hoffmann E, Vo D, John NS, Vertichio R, et al.

345 Screening all pregnant women admitted to Labor and Delivery for the virus responsible

346 for COVID-19. American Journal of Obstetrics and Gynecology. 2020 Apr 16. Available  
347 from: [https://www.ajog.org/article/S0002-9378\(20\)30472-5/fulltext](https://www.ajog.org/article/S0002-9378(20)30472-5/fulltext)  
348 15. Stringer SM. NYC Housing Brief: Hidden Households. Office of the New York  
349 City Comptroller. 2015 October [Cited 2020 Apr 15]. Available from:  
350 [https://comptroller.nyc.gov/wp-content/uploads/documents/Hidden\\_Households.pdf](https://comptroller.nyc.gov/wp-content/uploads/documents/Hidden_Households.pdf)  
351 16. Government of New York City. COVID-19 deaths, race, ethnicity. 2020 Apr 30  
352 [Cited 2020 May 2]. Available from:  
353 [https://www1.nyc.gov/assets/doh/downloads/pdf/imm/covid-19-deaths-race-ethnicity-](https://www1.nyc.gov/assets/doh/downloads/pdf/imm/covid-19-deaths-race-ethnicity-04302020-1.pdf)  
354 [04302020-1.pdf](https://www1.nyc.gov/assets/doh/downloads/pdf/imm/covid-19-deaths-race-ethnicity-04302020-1.pdf)





<b>Infection status</b>	<b>Health worker PPE</b>	<b>Counseling</b>	<b>Follow-up</b>
SARS-CoV-2 positive	<p>Full PPE during second stage and in Operating Room</p> <p>Gown, mask, gloves, eye protection for other interaction*</p> <p>Cohorting of infected mothers</p>	<p>Mother wears surgical mask and practices hand-hygiene</p> <p>Shared decision making on rooming-in of infant</p> <p>Breastfeed with a mask on or pump and have a healthy family member feed newborn</p> <p>Postpone maternal postpartum vaccination</p>	<p><u>Symptomatic</u>: daily phone-call by a provider for 7 days from + test <i>and</i> 72 hours afebrile with improving symptoms</p> <p><u>Asymptomatic</u>: twice-weekly phone call by a provider for 14 days from + test</p> <p>Counseling on isolation</p> <p>Tele-visit at 2 and 6 weeks postpartum</p>
SARS-CoV-2 negative	<p>Standard precautions</p> <p>Cohorting of uninfected mothers</p>	<p>Rooming-in of infant</p> <p>Routine breastfeeding</p> <p>Routine maternal postpartum vaccination counseling and administration</p>	<p>Tele-visit at 2 and 6 weeks postpartum</p>
Person Under Investigation (PUI)	<p>Full PPE during second stage and in Operating Room</p> <p>Gown, mask, gloves, eye protection for other interaction*</p> <p>Isolation (single room)</p>	<p>Mother wears mask and practices hand-hygiene</p> <p>Shared decision making on rooming-in of infant</p> <p>Breastfeed with a mask on or pump and have a healthy family member feed newborn</p> <p>Postpone maternal postpartum vaccination</p>	<p>Receives daily phone call by a provider until test result available</p> <p>Counseling on isolation</p> <p>Tele-visit at 2 and 6 weeks postpartum</p>

\*The use of N95 masks were added for all interactions with infected women and persons under investigation (PUI), once there was enough supply of these masks available.